OSCOTECInc.
KOSDAQ-listed drug developer whose out-licensed targeted lung cancer therapy has received approval from Korea's MFDS and the US FDA.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1998 and listed on KOSDAQ in 2007, OSCOTEC is a research-driven new drug development and biotech company. It operates a synthetic new drug development business, a functional-materials and related-products business, and a dental bone-graft-material business, and currently has two synthetic drug candidates in clinical trials. Its out-licensed targeted therapy for lung cancer, licensed to a domestic pharmaceutical company, has been approved by Korea's MFDS and the US FDA as a first-line treatment, either as monotherapy or in combination.
Products & technology
- Bone graft materials and membranesDental bone graft materials and membranes
- Functional materialsHealth functional food ingredient materials
Regulatory approvals
data.go.kr4 Korean MFDS device approvals · 1999–2014
- MFDSBarrier, intra oral, resorbable2014-02-25Product approval · Class 4제허 14-482 호
- MFDSBone graft material, animal source or other living things’ source2010-08-03Product approval · Class 4제허 10-771 호
- MFDSBone graft material, syntheticRevoked2006-05-10Product approval · Class 4제허 06-318 호
- MFDS치과용골이식재Revoked1999-12-10Product approval · Class 3제허 99-365 호
Clinical trials
data.go.kr3 MFDS clinical trial authorisations · 2021–2026 (Phase 1 3)
- Phase 1SKI-O-7032026-05-21
2 trial sites
- Phase 1OCT-5982025-11-18
12 trial sites
- Phase 1SKI-G-8012021-07-29
4 trial sites
R&D and key agreements
Source: DART corporate disclosure합성 신약 후보물질(2종) · 임상시험 진행중 · Synthetic small-molecule candidates for arthritis and oncology indications, currently in clinical trials
표적항암제(폐암 치료물질) · 폐암 · 한국 식약처·미국 FDA 승인 · Out-licensed to a domestic pharmaceutical company; approved as first-line monotherapy or combination therapy
Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Founded in 2004 and listed on KOSDAQ in 2011, NIBEC develops dental tissue regeneration biomaterials and peptide-based biomaterials.
Founded in 2016 and listed on KOSDAQ in 2017, DENTIS manufactures dental implants, medical LED lighting, and dental 3D printers.
KOSDAQ-listed medical device company manufacturing synthetic bioresorbable suture yarn and dental root canal filling materials.
Established in 2012 and listed on KOSDAQ in 2018, Osteonic manufactures implants for the CMF, Trauma, Sports Medicine, and Spine categories.
KOSDAQ-listed holding company making medical devices and biologics including bone graft rhBMP2 and knee implant TKR.
DIO Corporation, established in 1988 and listed on KOSDAQ in 2000, manufactures and sells dental implants.
Founded and KOSPI-listed in 2025, Samyang Biopharm develops medical devices, pharmaceuticals, and new drug candidates.
Founded in 1964 and KOSPI-listed in 1991, Shinhung manufactures and distributes dental equipment and materials.
Founded in 2013 and KOSDAQ-listed in 2018, T&R Biofab commercializes 3D bioprinting systems, bioinks, and biodegradable scaffolds.
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition